PharmaShots | Incisive News in 3 Shots

Subscribe Now

Krystal Biotech

Krystal Biotech doses First Patient with Inhaled KB707 in the P-I study for treating Locally Advanced or Metastatic Solid Tumors of the Lung

Krystal Biotech doses First Patient with Inhaled KB707 in the P-I study for treating Locally Advanced or Metastatic Solid Tumors o...

April 23, 2024

Krystal Biotech Reports EMA’s Validation of Vyjuvek for MAA to Treat Dystrophic Epidermolysis Bullosa (DEB)

Krystal Biotech Reports EMA’s Validation of Vyjuvek for MAA to Treat Dystrophic Epidermolysis Bullosa (DEB)

November 27, 2023

Krystal Biotech Reports the First Patient Dosing of KB407 in P-I Clinical Trial for the Treatment of Cystic Fibrosis

Krystal Biotech Reports the First Patient Dosing of KB407 in P-I Clinical Trial for the Treatment of Cystic Fibrosis

July 4, 2023

Krystal Biotech’s Vyjuvek (beremagene geperpavec) Receives the US FDA’s Approval for Dystrophic Epidermolysis Bullosa in Patients Aged ≥6 Months

Krystal Biotech’s Vyjuvek (beremagene geperpavec) Receives the US FDA’s Approval for Dystrophic Epidermolysis Bullosa in Patients...

May 22, 2023

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us